Antidepressants in elderly: Metaregression of double-blind, randomized clinical trials-Reference-Cited by-同舟云学术

Antidepressants in elderly: Metaregression of double-blind, randomized clinical trials

Published:2013-05 Issue:1-3 Volume:147 Page:1-8
ISSN:0165-0327
Container-title:Journal of Affective Disorders
language:en
Short-container-title:Journal of Affective Disorders

Author:

Calati Raffaella,Salvina Signorelli Maria,Balestri Martina,Marsano Agnese,De Ronchi Diana,Aguglia Eugenio,Serretti Alessandro

Publisher

Elsevier BV

Subject

Psychiatry and Mental health,Clinical Psychology

Reference87 articles.

1. Efficacy and tolerability of venlafaxine in geriatric outpatients with major depression: a double-blind, randomised 6-month comparative trial with citalopram;Allard;International Journal of Geriatric Psychiatry,2004

2. Efficacy and tolerability of fluoxetine in the elderly: a double-blind study versus amitryptiline;Altamura;International Clinical Psychopharmacology,1989

3. Empirically derived decision trees for the treatment of late-life depression;Andreescu;American Journal of Psychiatry,2008

4. Under-treatment of depression in older persons;Barry;Journal of Affective Disorders,2012

5. Sex differences in the pharmacokinetics and pharmacodynamics of antidepressants: an updated review;Bigos;Gender Medicine,2009

Cited by 75 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mood disorders and somatic comorbidities;International Clinical Psychopharmacology;2024-07-31

2. Considerations about the Treatment of Mood Disorders in Elderly Patients;Clinical Textbook of Mood Disorders;2024-05-30

3. Research status and global trends of late-life depression from 2004 to 2023: bibliometric analysis;Frontiers in Aging Neuroscience;2024-04-30

4. The ‘discontinuity hypothesis’ of depression in later life—clinical and research implications;Age and Ageing;2023-12-01

5. Factors Associated with Antidepressant Effects of Ketamine: A Reanalysis of Double-Blind Randomized Placebo-Controlled Trial of Intravenous Ketamine for Treatment-Resistant Depression;Pharmacopsychiatry;2023-10-16